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Abstract
Objective: We recently demonstrated that hypoxia, a key feature of IBD, increases enterochromaffin (EC) cell 5-HT secretion,
which is also physiologically regulated by the ADORA2B mechanoreceptor. Since hypoxia is associated with increased
extracellular adenosine, we wanted to examine whether this nucleotide amplifies HIF-1a-mediated 5-HT secretion.
Design: The effects of hypoxia were studied on IBD mucosa, isolated IBD-EC cells, isolated normal EC cells and the EC cell
tumor derived cell line KRJ-1. Hypoxia (0.5% O2) was compared to NECA (adenosine agonist), MRS1754 (ADORA2B receptor
antagonist) and SCH442146 (ADORA2A antagonist) on HIF signaling and 5-HT secretion. Antisense approaches were used to
mechanistically evaluate EC cells in vitro. PCR and western blot were used to analyze transcript and protein levels of HIF-1a
signaling and neuroendocrine cell function. An animal model of colitis was evaluated to confirm hypoxia:adenosine
signaling in vivo.
Results: HIF-1a is upregulated in IBD mucosa and IBD-EC cells, the majority (,90%) of which express an activated
phenotype in situ. Hypoxia stimulated 5-HT release maximally at 30 mins, an effect amplified by NECA and selectively
inhibited by MRS1754, through phosphorylation of TPH-1 and activation of VMAT-1. Transient transfection with Renilla
luciferase under hypoxia transcriptional response element (HRE) control identified that ADORA2B activated HIF-1a signaling
under hypoxic conditions. Additional signaling pathways associated with hypoxia:adenosine included MAP kinase and CREB.
Antisense approaches mechanistically confirmed that ADORA2B signaling was linked to these pathways and 5-HT release
under hypoxic conditions. Hypoxia:adenosine activation which could be reversed by 59-ASA treatment was confirmed in
a TNBS-model.
Conclusion: Hypoxia induced 5-HT synthesis and secretion is amplified by ADORA2B signaling via MAPK/CREB and TPH-1
activation. Targeting ADORA2s may decrease EC cell 5-HT production and secretion in IBD.
Citation: Damen R, Haugen M, Svejda B, Alaimo D, Brenna O, et al. (2013) The Stimulatory Adenosine Receptor ADORA2B Regulates Serotonin (5-HT) Synthesis
and Release in Oxygen-Depleted EC Cells in Inflammatory Bowel Disease. PLoS ONE 8(4): e62607. doi:10.1371/journal.pone.0062607
Editor: Jo¨rn Karhausen, Duke University Medical Center, United States of America
Received January 31, 2012; Accepted March 27, 2013; Published April 26, 2013
Copyright:  2013 Damen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These studies were funded by National Institutes of Health (NIH) R01DK080871 (Kidd) and Kontaktutvalget (Gustafsson) at St Olavs University Hospital
and Faculty of Medicine, NTNU, Trondheim, Norway. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mark.kidd@yale.edu
. These authors contributed equally to this work.
Introduction
Inflammatory Bowel Disease (IBD) is highly prevalent in
Europe and North America and a recent systematic review
demonstrated an increasing incidence (for UC: 6.3–24.3/100,000;
for CD: 5–20.2) [1]. This coupled with the long duration of the
illness make IBD one of the most common gastroenterological
diseases with a prevalence per 100,000 of 505 and 249 for UC and
322 and 319 for CD in Europe and the US, respectively [1]. The
etiology and pathogenesis of IBD, however, remains largely
unknown. While defects in local immune responses (both innate as
well as adaptive) to commensal microflora and food antigens are
assumed to play pathogenic roles in IBD [2,3], recent studies have
also demonstrated a role for the enterochromaffin (EC) cell in the
pathogenesis of this disease.
The EC cell is the most common neuroendocrine cell in the
epithelia lining the lumen of the gut and plays a key regulatory role
in gut secretion, motility, pain, and nausea [4]. The monoamine
neurotransmitter serotonin (5-hydroxytryptamine: 5-HT) has
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proven central in EC cell regulatory function and these cells
synthesize, store, and release the vast majority (95%) of the body’s
store of this amine [5]. EC cells function as ‘‘taste buds of the gut’’
and represent sensory transducers responding to mechanical
events, luminal acidification, or nutrients such as glucose and
short chain fatty acids, bile salt, tastants and olfactants [6–13]. In
addition, EC cell secretion can be activated by neural, bacterial
and immunological input [14,15]. Specifically, development of
IBD is associated with altered EC cell serotonin release [15,16].
Serotonin is considered to play a role in IBD through activation
of immune cell types which express receptors for this amine
[15,17]. TPH-1 knockout mice respond to chemically-induced
colitic agents with a less severe phenotype and delayed onset of
disease compared to wild-type mice treated in the same protocol
[15]. A variety of other studies [18–20] support a role for serotonin
in modulating immune signaling and the promotion of interactions
between innate and adaptive immune responses within the context
of gut inflammation.
Recently, rhythmic mechanical strain that mimics normal bowel
movements (mediated by ADORA2B receptors) has been identi-
fied to induce EC cell secretion and transcription of EC cell
secretory products – responses that are accentuated by neoplasia
[21]. We have also demonstrated that gut EC cells are oxygen-
responsive and alterations in O2 levels differentially activate HIF-
1a signaling and serotonin release [22]. This results in alterations
in serotonin production and secretion, effects amplified by
inflammation. In addition, to the latter, alterations in neuroendo-
crine signaling as well as activation of hypoxia-mediated responses
are features recently identified in a TNBS animal model [23] and
in IBD samples through transcriptome analyses [24].
Hypoxia is also strongly associated with an increase in
extracellular/mucosal adenosine levels [25] and with stabilization
of HIF-1a [26]. HIF-1a induces transcription and increases the
activity of 59ecto-nucleotidase (CD73), the enzyme that converts
AMP to adenosine [27]. CD73 also regulates transcription of the
ADORA2B receptor while suppressing transcription of the
adenosine re-uptake transporters, equilibrative nucleoside trans-
porters 1 and 2 (ENT1 and 2). Furthermore, CD73 decreases the
intracellular metabolism of adenosine by suppressing the tran-
scription of adenosine kinase [28]. In IBD, localized hypoxia
occurs as a result of chronic inflammation increasing the metabolic
needs of the tissue [29], and thus potentially up-regulates the
adenosine-ADORA pathway. ADORA2B is the predominant
ADORA receptor in colonic mucosa [30] and is also up-regulated
by TNFa [31]. Activation of the receptor is thought to regulate
cytokine production including IL-10 [32]; colitis is reduced in
knockout mice [33,34] suggesting a protective role.
We hypothesized that the increase in 5-HT observed in IBD
may, in part, be due to hypoxia increasing functional HIF-1a
which triggers an increase in extracellular adenosine signaling,
leading to increased production and secretion of 5-HT via
ADORA2B receptor activation. Gut mucosal tissue from IBD
patients, isolated EC cells and the well-characterized EC cell line
KRJ-1 were studied. This cell line possesses similar properties (e.g.
similar signaling pathways, enzyme activity and secretory prod-
ucts) and have similar responsiveness to stimuli, as normal EC cells
and is therefore an appropriate model to study 5-HT regulation
[13,21,35,36].
Materials and Methods
Materials
59-(N-Ethylcarboxamido) adenosine (NECA) (Sigma-Aldrich,
St. Louis, MO), a general adenosine receptor agonist that targets
all subtypes (ADORA1, 2A, 2B and 3), curcumin (a HIF-1a
inhibitor), SCH442146, a specific A2A receptor antagonist, and
MRS1754 hydrate, a specific A2B receptor antagonist were used
[37]. The following antibodies for western blot were obtained from
Cell Signaling Technology: PKA C-alpha (5842S), MAPK
(4695S), pMAPK (4370S), CREB (9197S), pCREB (9198S), Rb
IgG (7074S), Mouse IgG (7076S), from Abcam: VMAT-1 (58170)
and pTPH-1 (30574), from Alomone labs: A2B adenosine receptor
(AAR-003), from Novis Biologicals: TPH-1 (110-57629), from BD
Biosciences: HIF-1a (610958), from DAKO: Chromogranin A
(CgA: MO869) and from Sigma-Aldrich, b-actin (011M4793).
Human Samples
Tissue was collected from twenty-one patients (M:F= 12:9;
median age [range] = 53 yr [29–67]). CD tissue (n=12) was
obtained from patients who had undergone surgery for CD ileitis
(n=3) or colitis (n=9). Only grossly affected tissue was studied.
Macroscopically ‘‘normal’’ tissue was obtained from matched
samples when available (n=6). All tissue was collected between
2008 and 2013 at Yale University, Department of Surgery
following written informed consent from patients per protocol (Yale
University School of Medicine IRB approval, HIC#0805003870).
Animals
For the TNBS-colitis model, female Sprague Dawley rats (200–
250 g; Taconic) (n=9) were used including controls (vehicle
[0.6 ml 50%, ethanol]: n=3), TNBS (29.3 mg/ml, FLUKA; n=3)
or TNBS +5-aminosalicylic acid (5-ASA) (4 g/60 ml, volume
1.4 ml; n=3). Volumes were rectally instilled and colitis was
confirmed by endoscopy [23]. The study was terminated day 12
(after instillation) with blood and tissue collection. An additional 11
rats were used for EC cell isolation for the antisense studies.
ADORA2B Knockdown
A 19-mer oligonucleotide antisense corresponding to 461–480
of the rat ADORA2B receptor (NM_01716.1) was designed to
induce a steric obstacle for protein translation (Yale Medical
School Keck Oligonucleotide Synthesis Facility) [38]. Control
nucleotides were prepared with randomized sequence of matching
nucleotides per protocol. In these experiments, isolated EC cells
[39] were exposed to oligonucleotides (antisensense:
TCCCTCTTGCTCGTGTTCC, or control:
CTGTTCCGTCCGTTCCCTT –150 pmol) for 12 hrs (FITC-
uptake of oligonucleotides was noted as early as 2 hrs within cells,
with peri-nuclear uptake complete by 14–16 hrs), and then
assessed for mRNA, flow cytometry (receptor expression), secre-
tion and by western blot. These experiments were conducted
within 16 hrs following oligonucleotide uptake.
EC Cell Isolation
EC cells (.98% purity) were isolated from human or rat
samples by mucosal stripping, enzymatic digestion, and a combi-
nation of Nycodenz gradient fractionation and fluorescence
activated cell sorting (FACS) as described [13,16,35,39]. Approx-
imately 16106 cells were obtained per mucosal sample, a quantity
sufficient for real-time PCR, short-term culture and western blots.
Cell Culture Studies
KRJ-I cells [40] were maintained as floating aggregates in
Quantum 263 complete tumor growth medium (PAA) supple-
mented with penicillin (100 IU/ml) and streptomycin (100 ug/
ml). EC cells (normal, IBD or isolated from rat) were maintained
in short-term culture (,12 hrs after isolation) under the same
ADORA2B, IBD and EC Cell Serotonin Regulation
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conditions. All experiments were performed without antibiotics;
the cell line was mycoplasma free.
Hypoxic conditions were induced using a modular incubator
chamber (MIC-101, Billups-Rothenberg Inc, Del Mar, CA).
Briefly, short-term cultured EC cells or cultured KRJ-I cells
(48 hrs) were transferred to the humidified hypoxic chamber; the
chamber was flushed with CO2 for 4 min to maintain hypoxic
conditions (0.5% O2). KRJ-I cells (4610
5 cells/ml, n=6) were
seeded in 6 well plates (Falcon, BD, Franklin Lakes, NJ) NECA,
curcumin, SCH442146, MRS1754, and DMSO were added to
the wells. DMSO was added to the controls to compensate for
NECA and MRS1754 being solubilized in DMSO (,0.1% final
concentration). Cells were then incubated for 15 minutes. They
were then exposed to hypoxia for 0, 15, 30, 60, 120 and 240 mins.
After cells were harvested, whole-cell lysates were prepared by
adding 200 ml of ice-cold cell lysis buffer (106RIPA lysis buffer
[Millipore, Billerica, MA], complete protease inhibitor [Roche,
Indianapolis, IN], phosphatase inhibitor set 1&2 [Calbiochem,
Gibbstown, NJ], 100 mM PMSF [Roche], 200 mM Na3VO4
[Acros Organics], 12.5 mg/ml SDS [American Bioanalytical,
Natick, MA]). Tubes were centrifuged at 12,000 g for 20 min and
protein amount in the supernatant was quantified using the BCA
protein assay kit (Thermo Fisher Scientific, Rockford, IL).
Serotonin Secretion
5-HT levels were analyzed using commercially available ELISA
assays (5-HT: BA 10-0900; Rocky Mountain Diagnostics) as
previously described [13] in supernatant according to the
manufacturer’s instructions.
RLU Studies
The Cignal HIF Pathway Reporter Assay Kit (LUC) (CCS-
007L) was used to evaluate HIF signaling in EC cells (human,
ADORA2B-antisense treated rat) and in KRJ-I cells. Briefly, the
basis of this protocol is transient transfection with a HIF-
responsive luciferase construct that encodes the firefly luciferase
reporter gene under the control of a minimal (m)CMV promoter
and tandem repeats of the hypoxia transcriptional response
element (HRE). This is designed to monitor the activity of HIF-
regulated signal transduction pathways in cultured cells. Each
reporter is premixed with constitutively expressing Renilla lucifer-
ase, which serves as an internal control for normalizing trans-
fection efficiencies and monitoring cell viability. Short-term
cultured CD EC cells (10,000/well) or KRJ-I cells (10,000/well)
were transfected per protocol. Renilla luciferase activation follow-
ing ADORA2 activation was measured using the dual luciferase
assay (Glomax). The average maximum response per kit is 4 RLU;
in these experiments 2 RLU were identified.
Western Blot Analysis
Analyses were performed on 30 min hypoxia samples to
evaluate total TPH, p-TPH, total CREB, p-CREB, total ERK,
p-ERK, HIF-1a and PKA. Total protein lysates (20 mg) were
denaturated in SDS sample buffer, separated on a Tris-Glycine gel
(10%) and transferred to an Immobilon P (PVDF) membrane
(Milipore Corporation, Bedford, MA). After blocking (5% BSA for
60 min at room temperature) the membrane was incubated with
primary antibodies (Cell Signaling Technology and BD Bios-
ciences) in 5% BSA/PBS/Tween20 overnight at 4uC. The
membranes were incubated with the horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technology) for
60 min at room temperature and immunodetection was per-
formed using the Western LightningTM Plus-ECL (PerkinElmer,
MA). Blots were exposed on X-OMAT-AR films [40,41]. The
optical density of the appropriately sized bands was measured
using ImageJ software (NIH, USA).
RNA Isolation, Reverse Transcription and RT-PCR Analyses
RNA was extracted from mucosa (macroscopically normal
human or rat – normal, TNBS and TNBS-treated with 59ASA),
isolated normal and CD EC cells (16106), isolated normal and
ADORA2B-deficient (antisense) rat EC cells, and KRJ-I cells
(16106, n=4–7) using TRIZOLH (Invitrogen, Carlsbad, CA) then
cleaned (Qiagen, RNeasy kit, Qiagen, Valencia, CA) and
converted to cDNA (High Capacity cDNA Archive Kit, Applied
Biosystems, Carlsbad, CA) [36,42]. RT-PCR analyses were
performed using Assays-on DemandTM and the ABI 7900
Sequence Detection System [36,42]. Primer sets (HIF-1a (human
and rat) and ADORA2B (rat)) were all obtained from Applied
Biosystems and PCR mix on gels were performed to confirm
presence of single bands for each primer set. PCR Data was
normalized using the DDCT method; ALG9 was used as
a housekeeping gene[43] for human, GAPDH was used for rat
[23].
Immunostaining
An established immunohistochemical protocol was used to
identify target proteins [44,45]. Briefly, de-paraffinized sections
were incubated with a combination of antibodies (mouse HIF-1a
1:50 and goat polyclonal Chromogranin A 1:50) overnight at 4uC
and then with goat anti-mouse HRP conjugated (1:25) and donkey
anti-goat Alexa Fluor 488 conjugated (1:25). A Cy-5 tyramide
protocol was used to identify HIF-1a. 49,6-diamidino-2-phenylin-
dole (1:100) was used for nuclear identification. Bound antibodies
were visualized using immunofluorescent microscopy. A total of 10
clinical samples were examined, HIF-1a staining was identified
and quantitated as a subset of chromogranin A-positive cells.
Crohn’s mucosa was compared to macroscopically normal
mucosa.
Flow Cytometry
Rat EC cells (control or antisense at 12 hrs) were stained with
ADORA2B (1:500) and flow cytometry was conducted on a BD
FACS Aria Cell Sorter (BD Biosciences, Bedford MA). Positive
cells were identified for unstained, and the two EC cell populations
(antisense-treated and control).
Statistics
Results were expressed as mean6standard error (SEM). All
statistical analyses were performed using Prism 4 (GraphPad
Software, San Diego, CA). Results were compared between
control and stimulated cells using the Mann-Whitney test. A
p,0.05 was considered significant.
Results
HIF-1a Expression in Normal and IBD Mucosa and EC
Cells
HIF-1a transcripts were increased 3.5-fold in IBD mucosa
compared to macroscopically normal CD mucosa (Figure 1A). A
similar pattern was evident at the EC cell level, with CD EC cells
demonstrating a ,2.5-fold increase of HIF-1a mRNA compared
to normal EC cells. Assessment of protein expression confirmed
HIF-1a activation both in mucosa as well as in EC cells isolated
from Crohn’s mucosa (Figure 1B). Immunofluorescent staining of
CgA and HIF-1a (Figure 1C) identified double positive cells in
the mucosa (yellow arrows), confirming that the HIF-1a-positive
ADORA2B, IBD and EC Cell Serotonin Regulation
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cells were enteroendocrine. Significantly more EC cells (,90%,
p,0.001) were positive in Crohn’s mucosa than in macroscopically
normal mucosa (Figure 1D). These results suggest that EC cells
are exposed to hypoxia during inflammation and predominantly
exhibit an activated hypoxia-mediated signaling pathway (HIF-
1a).
The 5-HT Secretory Pathway
To evaluate whether adenosine-mediated HIF1a activation
increased 5-HT release from EC cells, we examined the effects of
hypoxia with and without ADORA2 antagonists on KRJ-I cells
over a 4 hr time period. Hypoxia significantly increased 5-HT
between 15 and 120 mins with a maximal effect (2.2 fold, p,0.05
versus no hypoxia, Figure 2A). Curcumin, a known HIF-1a
inhibitor through transcriptional repression [46], reversed hypox-
ia-mediated secretion at all time points. NECA, increased 5-HT
release (30–120 min), while MRS1754 but not SCH442146,
decreased it (15–120 min). This suggests that 5-HT release by
hypoxia is driven, at least in part, by activation of ADORA2B
receptors, and that adenosine can modulate 5-HT secretion.
We next evaluated expression of enzymes involved in 5-HT
synthesis and vesicle uptake (TPH-1 and VMAT-1) and in
secretion per se, chromogranin A (CgA). We focused on 30 mins
as this identified the time point at which 5-HT was maximally
secreted. Total protein levels of TPH-1 were unchanged by
hypoxia at 30 min (Figure 2B) but the phosphorylated form of
this enzyme, which identifies activated TPH-1, was increased. This
was amplified by NECA and inhibited by MRS1754. Analysis of
the ratio of activated to total TPH-1 protein identified that this was
increased 1.660.16 by hypoxia (p,0.05 vs. controls) and 2.460.2
(by NECA: p,0.05 vs. hypoxia) and was reduced to 0.9160.17 (by
MRS, p,0.05 vs. hypoxia). VMAT-1 functions to accumulate
cytosolic monoamines, like 5-HT, into secretory vesicles [47]. No
significant changes were noted for VMAT-1 by hypoxia, but levels
were significantly elevated by NECA (2.8360.07, p,0.05)
(Figure 2C), indicating that adenosine signaling activates 5-HT
uptake into vesicles. CgA is important for granulogenesis and
Figure 1. HIF-1a transcripts and protein in normal mucosa, IBD mucosa, isolated normal and IBD-EC cells. 1A) Transcript of HIF-1a was
significantly elevated in IBD-associated conditions (mucosa: 3.460.63 fold, cells: 2.460.41). 1B) Protein levels were significantly elevated in IBD-
associated conditions (mucosa: 12.263.4, cells: 2.660.36). 1C) Immunohistochemical staining of HIF-1a and Chromogranin A (white arrows) in
normal mucosa and Crohn’s mucosa identified co-staining (yellow arrows) predominantly in IBD mucosa. 1D) Quantitation identified significantly
more enteroendocrine cells to be HIF-1a positive in IBD mucosa. Mean6SEM, n= 4–7, *p=0.03 vs. normal mucosa, #p= 0.04 vs. normal EC cells,
##p,0.001 vs. normal EC cells. DAPI – nuclei (blue), FITC-CgA (green), Cy5-HIF-1a (red), co-localization (yellow). N–M=normal mucosa, IBD-M= IBD
mucosa, N–C=normal EC cells, IBD-C = IBD EC cells.
doi:10.1371/journal.pone.0062607.g001
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Figure 2. Effect of adenosine on the hypoxia-activated 5-HT pathway in KRJ-I cells. 2A) 5-HT was increased by hypoxia between 15–
120 min, with a maximal effect at 30 min (2.2860.12 fold). Curcumin and MRS1754 inhibited while NECA augmented secretion at all time points up
to 120 mins. SCH442146 had no significant effect. 2B) Total TPH-1 protein levels were unchanged after 30 min of hypoxia and after NECA or
MRS1754 stimulation. Phosphorylated TPH-1 was significantly increased under hypoxia (1.8060.26), was amplified by NECA (2.6660.28) and reduced
by MRS1754 to baseline. 2C) VMAT-1 protein levels were significantly increased (2.8360.31) by NECA during hypoxia and reduced by MRS1754
ADORA2B, IBD and EC Cell Serotonin Regulation
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secretion in neuroendocrine cells [48]. No alterations were
identified (Figure 2D). We interpret this to indicate that hypoxia
and adenosine directly activate pathways associated with the
formation of components essential to neuroendocrine secretion.
Directly Linking ADORA2B and HIF-1a
We next evaluated whether adenosine could activate HIF-1a. In
KRJ-I cells, 30 min hypoxia-induced HIF-1a protein expression
was reversed by curcumin (Figure 3A). Pre-treatment of cells with
NECA (15 mins prior to hypoxic challenge) significantly increased
HIF-1a protein (,1.3-fold) while MRS1754 significantly de-
creased this (,0.8-fold). SCH442146 had no effect.
To evaluate HIF-1a mediated signaling we undertook transient
transfection with a HIF-responsive firefly luciferase construct
under HRE-transcription control (Renilla luciferase-constructs) in
KRJ-I cells (Figure 3B) and in IBD-EC cells (Figure 3C). In
KRJ-I cells NECA activated luciferase (RLU) under normoxic
conditions while MRS1754 inhibited this; no effect was noted for
SCH442146. Under hypoxic conditions, NECA amplified lucifer-
ase activity (3-fold, p,0.05 vs. hypoxia) which was inhibited by
MRS1754 but not by SCH442146. In IBD-EC cells (which have
an activated HIF-1a–Figure 1A–C), activation of HRE-mediated
transcription was amplified by NECA (,1.5-fold RLU) under
normoxic conditions and inhibited by MRS1754. These results
suggest that adenosine, similar to a reduction in O2, can increase
HIF-1a protein levels and induce HRE-signaling which is
mediated via the ADORA type 2B receptor.
Analysis of Secretion-associated Signaling Pathways
We next evaluated whether signaling pathways related to 5-HT
release [21,49] were altered by hypoxia and adenosine. MAPK
kinease phosphorylation, although unchanged by hypoxia, was
(260.1). 2D) Chromogranin A protein levels did not change significantly after hypoxia or with the addition of NECA or MRS 1754. Mean6SEM, n= 3–
8, *p,0.05 vs. control, **p,0.05 vs. hypoxia. NS = not significant.
doi:10.1371/journal.pone.0062607.g002
Figure 3. HIF-1a, adenosine signaling and HRE activation. 3A) Curcumin inhibited (02260.04 fold) while NECA (1.2460.06 fold) stimulated
and MRS1754 (0.7460.02) inhibited HIF-1a protein levels compared to 30 minutes hypoxia in KRJ-I cells. SCH442146 had no effect. 3B) Transient
transfection with Renilla luciferase-encoding constructs in KRJ-I cells. Under normoxic conditions, NECA amplified activation of luciferase (RLU) while
MRS1754 inhibited this. Curcumin and SCH442416 had no effect. Hypoxic conditions activated RLU (1.8160.12), which was inhibited by curcumin and
MRS1754 and amplified by NECA. 3C) In IBD-EC cells, RLU was elevated in normoxic conditions. This could be reduced by curcumin and MRS1754 and
amplified by NECA. Mean6SEM, n=3–7, *p,0.05 vs. 30 min hypoxia or control, **p,0.05 vs. normoxic cells, #p,0.05 vs. 30 min hypoxia. NS =not
significant.
doi:10.1371/journal.pone.0062607.g003
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amplified by NECA, and reduced by MRS-1754 (Figure 4A).
This suggests that the ADORA2B receptor under hypoxic
conditions regulates MAP kinase activity – a known regulator of
5-HT secretion and TPH-1 phosphorylation [13,35].
CREB is an important transcription factor for TPH-1
transcription [50–52]. While not significantly increased by
hypoxia, the phosphorylated form was significantly increased by
NECA (Figure 4B), an effect that was reversed by MRS1754.
This suggests a role for ADORA-mediated signaling in the
regulation of hypoxia-mediated TPH1 transcription.
PKA, which mediates the adenosine signal for 5-HT production
and secretion under mechanical stress [21], was not significantly
changed by hypoxia and was not altered by either NECA or
MRS1754 (Figure 4C) suggesting that this pathway does not
regulate 5-HT secretion under these conditions.
Mechanistic Analysis of Hypoxia-adenosine Signaling
Pathways in EC Cells
We used an antisense approach to mechanistically dissect the
pathways associated with hypoxia-adenosine signaling in isolated
rat EC cells. ADORA2B antisense decreased transcription
(,50%) and was associated with a significant and almost complete
reduction in ADORA2B membrane protein expression
(Figure 5A). These cells could respond to hypoxia with 5-HT
release, but this was significantly lower than cells with normal
ADORA2B expression (Figure 5B). The latter cells responded
similar to human EC cells with adenosine-regulated hypoxia-
mediated 5-HT release, while the antisense-treated cells had
largely lost adenosine mediated effects. At a protein level, we
identified reduced pMAPK, pCREB and pTPH-1 in antisense
treated hypoxic cells (Figure 5C) identifying that these are the
principle pathways involved in adenosine-mediated 5-HT secre-
tion.
Hypoxia and ADORA2B in an Animal TNBS-induced
Colitis Model
Finally, we evaluated expression of HIF-1a and ADORA2B in
intestinal mucosa from a rat animal TNBS-induced colitis model
and evaluated the effect of 5-ASA. A real-time PCR analysis
confirmed significant upregulation of HIF-1a and ADORA2B
mRNA by TNBS (Figure 6A). The expression levels were
decreased by 5-ASA treatment. Protein levels followed a similar
expression pattern (Figure 6B). We interpret these data to
confirm activation of a hypoxia-adenosine pathway in a colitis
model – similar to observations in clinical samples.
Discussion
IBD is associated with abnormalities in the pro-inflammatory 5-
HT system. Previously, we have demonstrated that LPS and IL1b
induce a significantly elevated 5-HT response in IBD mucosa [16].
This may partly explain the hypersecretion of 5-HT noted in the
IBD disease process. As IBD mucosa is also exposed to significant
hypoxic stress, we examined the effects of hypoxia on EC cell 5-
HT secretion. We have identified that hypoxia induces 5-HT
secretion from EC cells and that this can be reversed by targeting
HIF-1a. HIF-1a is also associated with increased mucosal
adenosine availability, a known regulator of 5-HT production
and secretion [22]. Based on these observations, we investigated
the relationship between hypoxia, the ADORA signaling system
and 5-HT production/secretion in EC cells from CD and normal
mucosa to evaluate whether these factors are involved in the
amplified 5-HT production noted in IBD.
We demonstrated that HIF-1a was increased both at the
mRNA and protein levels in IBD mucosa, in an animal model of
colitis and in IBD-EC cells. The latter almost predominantly
(,90%) expressed a hypoxia activated phenotype and active HRE
signaling. These data confirm that the inflamed mucosa is under
hypoxic stress [53,54], and that EC cells, in particular, are
hypoxia-activated. We have previously identified increased
ADORA2B receptors both at protein and transcript levels in EC
cells isolated from IBD patients compared to controls [21]. In the
current study, we identified that adenosine amplified HIF-1a
expression and activity, which suggests that it can act as a positive
feedback mechanism for 5-HT synthesis and release.
Activating ADORA signaling via NECA increased 5-HT
release which could specifically be inhibited by MRS1754
identifying that, under low oxygen mucosal levels such as found
with hypoxia, EC cell secretion is regulated by adenosine and
specifically, via activation of ADORA2B receptors. The inhibitory
effect of MRS1754 was complete for the time period 15–90 mins
but at 120 mins, we could identify no inhibition by this agent. This
suggests that the adenosine (ADORA2B):hypoxic signaling path-
way occurs early (within 30 mins) and that other ADORA
receptors may play a role later in hypoxia-mediated 5-HT release;
it is unlikely that this is ADORA2A. A combination of HIF-1a
signal activation and adenosine-mediated ADORA2 signaling
appears to play important roles in EC cell 5-HT secretion in IBD.
HIF-1a itself may directly regulate transcription of the rate-
limiting enzyme in 5-HT synthesis TPH-1. The promoter region
of this gene encodes hypoxia responsive elements (HRE) [55];
hypoxia may therefore directly increase 5-HT production by
increasing TPH-1 expression. Transcriptional alterations in TPH-
1 were not consistently identified in our current study (data not
shown) suggesting the major route regulating 5-HT release
occurred at the level of protein regulation and via pathways
cross-activated by HIF-1a signaling.
Figure 4. Effects of hypoxia and adenosine on signaling
pathways. 4A) Phosphorylated MAPK was not significantly altered
by hypoxia but was amplified by NECA (1.2960.06)and reduced by
MRS1754 (0.4060.09); total MAPK protein amount was unchanged. 4B)
Neither total CREB nor phosphorylated CREB were altered after 30 min
of hypoxia. NECA, however, stimulated p CREB compared (1.5560.07);
this was reduced by MRS1754 (0.760.12). 4C) Free catalytically active
PKA protein levels were unchanged after 30 min of hypoxia, as well as
after NECA and MRS1754. Mean6SEM, n=5–8.
doi:10.1371/journal.pone.0062607.g004
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Figure 5. Analysis of 5-HT release and signaling pathways in ADORA2B-deficient rat EC cells. 5A) A 12 hr antisense approach inhibited
ADORA2B transcript (real-time PCR) and protein expression (membrane-bound, flow cytometry) in isolated rat EC cells. Membrane expression was
reduced to an estimated 5% of non-targeted cells. 5B) In non-targeted cells, 5-HT release was elevated by hypoxia and inhibited by curcumin.
Adenosine signaling responses were similar to human EC cells. Antisense reduced hypoxic-mediated responses (compared to controls) and
ameliorated cell responses to NECA and MRS1754. 5C) Western blot identified decreased pMAPK (0.5660.09), pCREB (0.7560.11) and pTPH-1
(0.6360.07) in antisense treated cells confirming down-regulation of these pathways with loss of ADORA2B expression under hypoxic conditions.
Mean6SEM, n=3. *p,0.05 vs. control, **p,0.05 vs hypoxia, #p,0.05 vs. hypoxia (in non-antisense treated cells). NS =not significant.
doi:10.1371/journal.pone.0062607.g005
Figure 6. Analysis of HIF-1a and ADORA2B in mucosa from the animal TNBS-induced colitis model with or without 5-ASA-
treatment. 6A) TNBS was associated with a significant elevation in HIF-1a and ADORA2B transcripts. Treatment with 5-ASA reversed these values to
those similar to untreated rats. 6B) Protein expression was elevated by TNBS (HIF-1a: 1.6860.11; ADORA2B: 1.3760.09) and reversed by 5-ASA in
mucosa. Mean6SEM, n= 3. *p,0.05 versus control, **p,0.05 versus TNBS.
doi:10.1371/journal.pone.0062607.g006
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We have previously demonstrated that the adenosine/
ADORA2B/cAMP/PKA/CREB pathway plays a pivotal role in
regulating 5-HT secretion from the EC cell when subject to
mechanical stress [21]. In the current study, we demonstrated that
the activation of the ADORA2B receptor was important for the
increased levels of 5-HT noted during hypoxia. The intracellular
signaling pathways involved in the hypoxic response, however,
exhibit differences to that identified for EC cell mechano-
responsivity. We failed to detect differences in PKA suggesting
that activation of cAMP-responsive pathways is not PKA-
regulated under these conditions. In contrast, we identified
ADORA2B mediated activation of MAPK signaling as well as
increased phosphorylation (and thereby activation) of TPH-1.
TPH-1 is a MAPK target and it is likely, under hypoxic conditions,
that MAPK phosphorylates and thereby activates this enzyme,
leading to an increase in 5-HT synthesis. Antisense approaches
mechanistically confirmed roles for both MAPK as well as TPH-1
in EC cells under hypoxic conditions.
Other factors involved in 5-HT secretion were altered by
adenosine-ADORA2B signaling. Specifically, protein levels of the
rate-limiting enzyme involved in 5-HT vesicular accumulation,
VMAT1, were increased. We postulate that the excess 5-HT
produced by activated TPH-1, is actively transported into vesicles
which then provides a large pool for release. We interpret this to
demonstrate that vesicle maturation [47,48], is directly regulated
by adenosine under hypoxic conditions.
Adenosine plays a complex role in IBD. Apart from activating
EC cell 5-HT secretion, this nucleotide can also decrease SERT
activity [56]; the combination resulting in a increased mucosal 5-
HT signal. One prediction, given the pro-inflammatory activity of
5-HT, is an exacerbation of colitis under these conditions. Other
studies have demonstrated an increased severity of colitis in
ADORA2B2/2 mice suggesting that targeting this receptor may
be a potential therapeutic target. Currently, loss of ADORA2B is
considered to result in down-regulation of IL10 production, with
accentuation of colitis. Our studies indicate that loss of
ADORA2B decreases 5-HT and, presumably, the mucosal
aminergic signal.
Elevated mucosal adenosine, induced in hypoxic conditions or
during abnormalities in peristalsis, may activate EC cell 5-HT
synthesis and release, and reduce enterocyte-mediated SERT
production with a resultant overall increase in 5-HT pro-
inflammatory signaling. In the context of ADORA signaling, our
studies and others, highlight both the complexity of the mucosal
pathways involved in IBD as well as the importance of delineating
individual cell signaling. This may help better direct targeted
therapy.
Author Contributions
Conceived and designed the experiments: RD MH BS BIG MK.
Performed the experiments: RD MH BS DA OB MK. Analyzed the
data: RD MH BS DA OB BIG MK. Contributed reagents/materials/
analysis tools: RD MH BS RP BIG MK. Wrote the paper: RD MH BS RP
BIG MK.
References
1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, et al. (2012) Increasing
incidence and prevalence of the inflammatory bowel diseases with time, based
on systematic review. Gastroenterology 142: 46–54 e42.
2. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory
bowel disease. Nature 448: 427–434.
3. Strober W (2006) Immunology. Unraveling gut inflammation. Science 313:
1052–1054.
4. Gershon MD, Tack J (2007) The serotonin signaling system: from basic
understanding to drug development for functional GI disorders. Gastroenter-
ology 132: 397–414.
5. Bertaccini G (1960) Tissue 5-hydroxytryptamine and urinary 5-hydroxyindo-
leacetic acid after partial or total removal of the gastro-intestinal tract in the rat.
J Physiol 153: 239–249.
6. Kalhan A, Vazquez M, Jasani B, Stott J, Neal J, et al. Adenosine Receptor
Signal Pathways in Neuroendocrine Tumours 2008; London. Bioscientifica.
7. Kellum J, Albuerqueque F, Stoner M, Harris R (1999) Stroking human jejunal
mucosa induces 5-HT release and Cl- secretion via afferent neurons and 5-HT4
receptors. Am J Physiol 277: G515–G520.
8. Kellum J, Jaffe B (1976) Validation and application of a radioimmunoassay for
serotonin. Gastroenterolology 70: 516.
9. Bulbring E, Lin R (1958) The effect of intraluminal application of 5-
hydroxytryptamine and 5-hydroxytryptophan on peristalsis: the local production
of 5-HT and its release in relation to intraluminal pressure and propulsive
activity. J Physiol 140: 381.
10. Zhu J, Wu X, Owyang C, Li Y (2001) Intestinal serotonin acts as a paracrine
substance to mediate vagal signal transmission evoked by luminal factors in the
rat. J Physiol 530: 431–442.
11. Raybould H, Glatzle J, Robin C, Meyer J, Phan T, et al. (2003) Expression of 5-
HT3 receptors by extrinsic duodenal afferents contribute to intestinal inhibition
of gastric emptying. Am J Physiol 284: G367–372.
12. Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, et al. (2003)
Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in
rats. Am J Physiol 284: R1269–1276.
13. Kidd M, Modlin IM, Gustafsson BI, Drozdov I, Hauso O, et al. (2008) Luminal
regulation of normal and neoplastic human EC cell serotonin release is mediated
by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver
Physiol 295: G260–272.
14. Cooke HJ (2000) Neurotransmitters in neuronal reflexes regulating intestinal
secretion. Ann N Y Acad Sci 915: 77–80.
15. Ghia JE, Li N, Wang H, Collins M, Deng Y, et al. (2009) Serotonin has a key
role in pathogenesis of experimental colitis. Gastroenterology 137: 1649–1660.
16. Kidd M, Gustafsson BI, Drozdov I, Modlin IM (2009) IL1beta- and LPS-
induced serotonin secretion is increased in EC cells derived from Crohn’s
disease. Neurogastroenterol Motil 21: 439–450.
17. Leon-Ponte M, Ahern GP, O’Connell PJ (2007) Serotonin provides an accessory
signal to enhance T-cell activation by signaling through the 5-HT7 receptor.
Blood 109: 3139–3146.
18. Muller T, Durk T, Blumenthal B, Grimm M, Cicko S, et al. (2009) 5-
hydroxytryptamine modulates migration, cytokine and chemokine release and
T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 4:
e6453.
19. Idzko M, Panther E, Stratz C, Muller T, Bayer H, et al. (2004) The
serotoninergic receptors of human dendritic cells: identification and coupling to
cytokine release. J Immunol 172: 6011–6019.
20. Li N, Ghia JE, Wang H, McClemens J, Cote F, et al. (2011) Serotonin activates
dendritic cell function in the context of gut inflammation. Am J Pathol 178: 662–
671.
21. Chin A, Svejda B, Gustafsson BI, Granlund A, Sandvik AK, et al. (2011) The
role of mechanical forces and adenosine in the regulation of intestinal
enterochromaffin cell serotonin secretion. Am J Physiol Gastrointest Liver
Physiol 28: 28.
22. Haugen M, Damen R, Svejda B, Gustafsson B, Pfragner R, et al. (2012)
Differential signal pathway activation and 5-HT function: the role of gut
enterochromaffin cells as oxygen sensors. Am J Physiol Gastrointest Liver
Physiol 303: G1164–1173.
23. Brenna Ø, Furnes M, Drozdov I, Granlund A, Flatberg A, et al. (2013)
Endoscopic, histological and transcriptomic characterization of TNBS-colitis in
rats, a model for IBD. Plos One 8: e54543.
24. Van Beelen Granlund A, Flatberg A, Ostvik A, Drozdov I, Gustafsson B, et al.
(2013) Whole Genome Gene Expression Meta-analysis of Inflammatory Bowel
Disease Colon Mucosa demonstrates lack of major differences between Crohn’s
Disease and Ulcerative Colitis. Plos One 8: e56818.
25. Eltzschig HK (2009) Adenosine: an old drug newly discovered. Anesthesiology
111: 904–915.
26. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal
hypoxia to the nucleus. Cell 107: 1–3.
27. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, et al. (2002)
Ecto-59-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates
permeability changes in intestinal epithelia. J Clin Invest 110: 993–1002.
28. Sitkovsky MV (2008) Damage control by hypoxia-inhibited AK. Blood 111:
5424–5425.
29. Taylor CT, Colgan SP (2007) Hypoxia and gastrointestinal disease. J Mol Med
85: 1295–1300.
30. Strohmeier GR, Reppert SM, Lencer WI, Madara JL (1995) The A2b adenosine
receptor mediates cAMP responses to adenosine receptor agonists in human
intestinal epithelia. J Biol Chem 270: 2387–2394.
31. Kolachala V, Asamoah V, Wang L, Obertone TS, Ziegler TR, et al. (2005)
TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in
ADORA2B, IBD and EC Cell Serotonin Regulation
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e62607
intestinal epithelial cells: a basis for A2bR overexpression in colitis. Cell Mol Life
Sci 62: 2647–2657.
32. Nemeth ZH, Lutz CS, Csoka B, Deitch EA, Leibovich SJ, et al. (2005)
Adenosine augments IL-10 production by macrophages through an A2B
receptor-mediated posttranscriptional mechanism. J Immunol 175: 8260–8270.
33. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, et al. (2009)
Contribution of adenosine A2B receptors to inflammatory parameters of
experimental colitis. J Immunol 182: 4957–4964. doi: 4910.4049/jimmu-
nol.0801324.
34. Kolachala VL, Vijay-Kumar M, Dalmasso G, Yang D, Linden J, et al. (2008)
A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenter-
ology 135: 861–870. doi: 810.1053/j.gastro.2008.1005.1049. Epub 2008 May
1021.
35. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC (2006) The
functional characterization of normal and neoplastic human enterochromaffin
cells. J Clin Endocrinol Metab 91: 2340–2348.
36. Kidd M, Eick GN, Modlin IM, Pfragner R, Champaneria MC, et al. (2007)
Further delineation of the continuous human neoplastic enterochromaffin cell
line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol
Endocrinol 38: 181–192.
37. Kalhan A, Gharibi B, Vazquez M, Jasani B, Neal J, et al. (2011) Adenosine
A(2A) and A (2B) receptor expression in neuroendocrine tumours: potential
targets for therapy. Purinergic Signal 27: 27.
38. Lauffer JM, Tang LH, Zhang T, Hinoue T, Rahbar S, et al. (2001) PACAP
mediates the neural proliferative pathway of Mastomys enterochromaffin-like
cell transformation. Regul Pept 102: 157–164.
39. Kidd M, Modlin IM, Eick GN, Champaneria MC (2006) Isolation, functional
characterization, and transcriptome of Mastomys ileal enterochromaffin cells.
Am J Physiol Gastrointest Liver Physiol 291: G778–791. Epub 2006 Feb 2002.
40. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, et al. (2011)
Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase
inhibition reflect growth factor-mediated PI3K feedback loop activation via
ERK1/2 and AKT. Cancer.
41. Kidd M, Modlin IM, Pfragner R, Eick GN, Champaneria MC, et al. (2007)
Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming
growth factor-beta1-mediated regulatory abnormalities including up-regulation
of C-Myc and MTA1. Cancer 109: 2420–2431.
42. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, et al. (2005) Microsatellite
instability and gene mutations in transforming growth factor-beta type II
receptor are absent in small bowel carcinoid tumors. Cancer 103: 229–236.
43. Kidd M, Nadler B, Mane S, Eick G, Malfertheiner M, et al. (2007) GeneChip,
geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR.
Physiol Genomics 30: 363–370.
44. Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM (2007) Role of CCN2/
CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric
carcinoid development. Am J Physiol Gastrointest Liver Physiol 292: G191–200.
45. Kidd M, Modlin IM, Mane SM, Camp RL, Shapiro MD (2006) Q RT-PCR
detection of chromogranin A: a new standard in the identification of
neuroendocrine tumor disease. Annals of Surgery 243: 273–280.
46. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, et al. (2006) Curcumin inhibits
hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15:
1557–1562.
47. Eiden LE, Schafer MK, Weihe E, Schutz B (2004) The vesicular amine
transporter family (SLC18): amine/proton antiporters required for vesicular
accumulation and regulated exocytotic secretion of monoamines and acetylcho-
line. Pflugers Arch 447: 636–640.
48. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, et al. (2010)
Chromogranin A–biological function and clinical utility in neuro endocrine
tumor disease. Ann Surg Oncol 17: 2427–2443.
49. Damen R, Haugen M, Svejda B, Pfragner R, Modlin I, et al. (2013) The
stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis
and release in oxygen-depleted EC cells in IBD. Plos One (in press).
50. Zubenko GS, Jones ML, Estevez AO, Hughes HB 3rd, Estevez M (2009)
Identification of a CREB-dependent serotonergic pathway and neuronal circuit
regulating foraging behavior in Caenorhabditis elegans: a useful model for
mental disorders and their treatments? Am J Med Genet B Neuropsychiatr
Genet 150B: 12–23.
51. Garcia-Osta A, Del Rio J, Frechilla D (2004) Increased CRE-binding activity
and tryptophan hydroxylase mRNA expression induced by 3,4-methylenediox-
ymethamphetamine (MDMA, ‘‘ecstasy’’) in the rat frontal cortex but not in the
hippocampus. Brain Res Mol Brain Res 126: 181–187.
52. Drozdov I, Svejda B, Gustafsson B, Mane S, Pfragner R, et al. (2011) Gene
Network Inference and Biochemical Assessment delineates GPCRPathways and
CREB Targets in Small Intestinal Neuroendocrine Neoplasia Plos One 6:
e22457.
53. Pierdomenico M, Stronati L, Costanzo M, Vitali R, Di Nardo G, et al. (2011)
New insights into the pathogenesis of inflammatory bowel disease: transcription
factors analysis in bioptic tissues from pediatric patients. J Pediatr Gastroenterol
Nutr 52: 271–279.
54. Hirota SA, Beck PL, MacDonald JA (2009) Targeting hypoxia-inducible factor-
1 (HIF-1) signaling in therapeutics: implications for the treatment of
inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov 3: 1–16.
55. Pocock R, Hobert O (2010) Hypoxia activates a latent circuit for processing
gustatory information in C. elegans. Nat Neurosci 13: 610–614.
56. Matheus N, Mendoza C, Iceta R, Mesonero JE, Alcalde AI (2009) Regulation of
serotonin transporter activity by adenosine in intestinal epithelial cells. Biochem
Pharmacol 78: 1198–1204.
ADORA2B, IBD and EC Cell Serotonin Regulation
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e62607
